Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease

During the past decade, transdermal delivery systems (TDS) have become increasingly important for treating neurologic and psychiatric disorders. The rivastigmine patch was the first patch to be approved to treat Alzheimer’s disease (AD). The 9.5 mg/24 h patch has equal efficacy to the capsules and r...

Descripción completa

Detalles Bibliográficos
Autores principales: Wentrup, Andreas, Oertel, Wolfgang H, Dodel, Richard
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761169/
https://www.ncbi.nlm.nih.gov/pubmed/19920911

Ejemplares similares

Ejemplares similares